Abstracts Archive - Page 822 of 2425 - ACR Meeting Abstracts

Abstract Number: 954 • 2019 ACR/ARP Annual Meeting
Physical Therapy and Opioid Use in Knee Osteoarthritis
Deepak Kumar¹, Christine Peloquin ², Andrew Stokes ³, Lee Marinko ⁴, James Camarinos ⁴, David Felson ⁵ and Maureen Dubreuil ², ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, ³Boston University School of Public Health, Boston, ⁴Boston University, Boston, ⁵Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of chronic pain in older adults. Physical therapy (PT) decreases OA pain and consequently may reduce burden…
Abstract Number: 955 • 2019 ACR/ARP Annual Meeting
Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study
Tom Hahn ¹, Eric Sayre ², Maria Victoria Goycochea-Robles ³ and Diane Lacaille⁴, ¹Department of Medicine, University of British Columbia, Vancouver, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Unidad de Investigación en Epidemiologia HGR 1, Mexican Institute of Social Security -, Mexico City, Mexico, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Cardiovascular diseases (CVD) are increased in RA and lead to premature mortality. Statins are effective at preventing incidence of, and mortality from, CVD; yet,…
Abstract Number: 956 • 2019 ACR/ARP Annual Meeting
The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study
Carol Hitchon¹, Charles Bernstein ¹, James Bolton ¹, Renée El-Gabalawy ¹, John Fisk ², Alan Katz ¹, Lisa Lix ³, James Marriott ¹, Scott Patten ⁴, Christine Peschken ³, Jitender Sareen ¹, Alexander Singer ¹, Randy Walld ¹ and Ruth Ann Marrie ¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³University of Manitoba, Winnipeg, Canada, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: Psychiatric comorbidity is increased in rheumatoid arthritis (RA) and may complicate medical care, increasing the risk of adverse health outcomes and health care utilization…
Abstract Number: 957 • 2019 ACR/ARP Annual Meeting
Alterations in Cholesterol Homeostasis Regulate Autoimmunity/Age-associated B Cells
Zhu Chen¹, Michela Manni ¹, Danny Flores-Castro ¹, Tania Pannellini ¹ and Alessandra Pernis ², ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, ²1.Autoimmunity and Inflammation Program, Hospital for Special Surgery. 2.David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery. 3.Department of Medicine, Weill Cornell Medical College, Cornell University, New York
Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
Abstract Number: 958 • 2019 ACR/ARP Annual Meeting
Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus
Kazuhiko Higashioka¹, Masahiro Ayano ², Yasutaka Kimoto ³, Hiroki Mitoma ², Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ¹, Takahiko Horiuchi ⁴ and Hiroaki Niiro ⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁵Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, multi-systemic disease that potentially affects any organ in the body. Clinical efficacy of B cell-targeting therapy underscores…
Abstract Number: 959 • 2019 ACR/ARP Annual Meeting
A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
Andrew Kinloch¹, Aazam Mohsin ¹, Yuta Asano ¹, Carole Henry ¹, Nirit Mor Vaknin ², Maureen Legendre ², Patrick Wilson ¹, David Markovitz ² and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Vimentin is a dominant target of B-cells selected in lupus tubulointerstial inflammation (TII), a predictor of renal failure. The origins of anti-vimentin antibodies (AVA)…
Abstract Number: 960 • 2019 ACR/ARP Annual Meeting
Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins
Zihao Zheng ¹, Lauren Fahmy ¹, Alan Bridges ², Michael Newton ¹ and Miriam Shelef¹, ¹University of Wisconsin - Madison, Madison, ²William S. Middleton Memorial Veterans Hospital, Madison
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are the main diagnostic and pathologic autoantibodies in rheumatoid arthritis. However, autoantibodies develop against proteins with…
Abstract Number: 961 • 2019 ACR/ARP Annual Meeting
Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody
Ai Kuzumi¹, Ayumi Yoshizaki ¹, Takemichi Fukasawa ¹, Satoshi Ebata ¹, Yoshihide Asano ¹ and Shinichi Sato ¹, ¹University of Tokyo Graduate School of Medicine, Department of Dermatology, Tokyo, Japan
Background/Purpose: B cell depletion therapy with anti-CD20 antibody rituximab has emerged as a potential treatment for systemic sclerosis (SSc). Rituximab, which has been used to…
Abstract Number: 962 • 2019 ACR/ARP Annual Meeting
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Erin Wilfong¹, Jennifer Young-Glazer ², Elise Rizzi ³, Rosemarie Dudenhofer ², Leslie Crofford ¹ and Peggy Kendall ², ¹Vanderbilt University, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville
Background/Purpose: Systemic sclerosis (SSc) is a severe systemic disease characterized by fibrosis of the skin and visceral organs. While protein biomarkers of lung damage, e.g.…
Abstract Number: 963 • 2019 ACR/ARP Annual Meeting
Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNα and TNFRII in ANA+ Healthy Individuals
Aleksandra Bylinska¹, Samantha Slight-Webb ¹, Miles Smith ², Susan R. Macwana ¹, Nicolas Dominguez ¹, Eliza F. Chakravarty ³, Joan T. Merrill ⁴, Judith James ³ and Joel Guthridge ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Loss of systemic self-tolerance leading to anti-nuclear autoantibody (ANAs) by B cells is a hallmark of SLE. However, up to 20% of healthy female…
Abstract Number: 964 • 2019 ACR/ARP Annual Meeting
Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Jennifer Young-Glazer¹, Erin Wilfong ², Peggy Kendall ¹, Rachel Bonami ¹ and Leslie Crofford ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 965 • 2019 ACR/ARP Annual Meeting
Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
Yong Dae Shin¹, Jae-Hun Jung ¹, Eun Kyung Kim ¹, SOHEE IM ¹, Sunah Jun ¹, NamYoun Kim ¹, SeungHwarn Jeong ¹, Hyaejung Hyun ¹ and Joon Seok Park ¹, ¹Daewoong Life science research institute, Yongin-si, Republic of Korea
Background/Purpose: Janus Kinase (JAK) and Bruton's tyrosine kinase (BTK) play critical roles in activation and function of T cells and B cells. Dysregulation of this…
Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Laura van Dam¹, Jelle Oskam ², Sylvia Kamerling ², Eline Arends ², Edwin Bredewold ², Magda Berkowska ², Jacques van Dongen ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
Abstract Number: 967 • 2019 ACR/ARP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Sunil Nagpal¹, Qingxuan Song ², Matthew Loza ³, Yanqing Chen ⁴, Xuefeng Yin ², Leon Cheng ⁴, Michael Huber ⁴, Frédéric Baribaud ³, Fang Shen ¹ and Navin Rao ¹, ¹Janssen R&D, Spring House, PA, ²Janssen R&D, Spring House, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research, La Jolla
Background/Purpose: Bruton’s tyrosine kinase (BTK), a TEC family non-receptor kinase, is expressed in B cells and myeloid cells. BTK relays signaling downstream of B cell…
Abstract Number: 968 • 2019 ACR/ARP Annual Meeting
Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion ², Amber Hummel ¹, Eva Carmona ¹, Tobias Peikert ¹, Carol Langford ³, Peter Merkel ⁴, Paul Monach ⁵, Philip Seo ⁶, Robert Spiera ⁷, E William St. Clair ⁸, Fernando Fervenza ¹, Kristina Harris ⁹, John Stone ¹⁰, Jacques-Olivier Pers ¹¹, Peter Heeringa ¹², Wayel Abdulahad ¹³, Ulrich Specks ¹⁴ and Divi Cornec ¹¹, ¹Mayo Clinic, Rochester, MN, ²Université de Bretagne Occidentale, Brest, Bretagne, France, ³Cleveland Clinic, Cleveland, OH, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Johns Hopkins Medicine, Baltimore, MD, ⁷Hospital for Special Surgery, New York, NY, ⁸Duke, Raleigh, ⁹Immune Tolerance Network, Bethesda, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Universite de Bretagne Occidentale, Brest, Bretagne, France, ¹²Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, ¹³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, ¹⁴Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: We previously developed a method to recognize proteinase 3 (PR3)-specific B cells by flow cytometry. We reported that, in a small number of subjects,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].